menu
    • menu

    Company profile for Lynk Pharmaceuticals

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lynk Pharmaceuticals: is a clinical stage company dedicated to discovering and developing novel medicines to treat oncology, immunology and inflammatory diseases. Lynk Pharmaceuticals was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with collectively more than 7 decades of rich experiences in drug discovery. Driven by a higher purpose, Lynk Pharmaceuticals aims at growing into a market leader for ...
    Lynk Pharmaceuticals: is a clinical stage company dedicated to discovering and developing novel medicines to treat oncology, immunology and inflammatory diseases. Lynk Pharmaceuticals was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with collectively more than 7 decades of rich experiences in drug discovery. Driven by a higher purpose, Lynk Pharmaceuticals aims at growing into a market leader for developing innovative therapies to address unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lynk PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou, Zhejiang 310018, China
    Telephone
    Telephone
    +86 0571-87711179
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.lynkpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lynk Report Positive Ph3 Data for RA Arthritis Drug Zemprocitinib
    Lynk Report Positive Ph3 Data for RA Arthritis Drug Zemprocitinib

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-positive-phase-iii-topline-data-of-zemprocitinib-lnk01001-in-rheumatoid-arthritis-302657981.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Lynk Pharma, Formation Bio Ink Exclusive Deal For LNK01006
    Lynk Pharma, Formation Bio Ink Exclusive Deal For LNK01006

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-and-formation-bio-enter-exclusive-development-and-licensing-agreement-for-lnk01006-302637950.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Lynk Pharma Gets FDA Nod For Allosteric TYK2 Inhibitor LNK01006
    Lynk Pharma Gets FDA Nod For Allosteric TYK2 Inhibitor LNK01006

    02 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-fda-ind-approval-of-its-allosteric-tyk2-inhibitor-lnk01006-302629050.html

    PR NEWSWIRE
    02 Dec 2025
    Share Share
    Lynk Pharma Reveals Phase II Results For LNK01004
    Lynk Pharma Reveals Phase II Results For LNK01004

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-key-phase-ii-clinical-results-of-lnk01004-for-the-treatment-of-patients-with-moderate-to-severe-atopic-dermatitis-302618650.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share
    Lynk Pharma Reports Positive Phase 1b Results For LNK01004 In Dermatitis
    Lynk Pharma Reports Positive Phase 1b Results For LNK01004 In Dermatitis

    13 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-positive-results-from-phase-1b-clinical-study-of-lnk01004-for-the-treatment-of-atopic-dermatitis-302219928.html

    PR NEWSWIRE
    13 Aug 2024
    Share Share
    Lynk Announced First Rheumatoid Arthritis Patient Dosed in PIII of LNK01001
    Lynk Announced First Rheumatoid Arthritis Patient Dosed in PIII of LNK01001

    20 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announced-first-rheumatoid-arthritis-patient-dosed-in-phase--clinical-study-of-lnk01001-302019129.html

    PR NEWSWIRE
    20 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search